filmov
tv
LuPSMA: The Newest Treatment Class for Advanced Prostate Cancer
Показать описание
2021 Prostate Cancer Foundation (PCF) Scientific Retreat
Speaker: Prof. Michael Hofman
Speaker: Prof. Michael Hofman
LuPSMA: The Newest Treatment Class for Advanced Prostate Cancer
Highlights on Lu-PSMA-617 in taxane-naive patients with mCRPC: The PSMAfore study
TheraP Study: Lu-PSMA vs. cabazitaxel #ASCO20 #ANZUP
ECLIPSE - A Randomized Phase 3 Trial for 177-Lu-PSMA-I&T in patients with mCRPC
Lu-PSMA Radioligand Therapy
177 Lu PSMA Treatment for Prostate Cancer (Update: FDA approved on 3/23/22)
2024 Update | Lu-177 (Pluvicto), Actinium & New #ProstateCancer AntiBody | Dr. Nat Lenzo #AlexSc...
Lu-PSMA: A Breakthrough Treatment for Advanced Prostate Cancer
Lutetium-177: PSMA Guided Treatment | #ProstateCancer | #MarkScholzMD | #PCRI
PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC
VISION trial supports LuPSMA-targeting therapy for mCRPC | Michael Morris
Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-p......
Prostate Cancer in 2024: Recent Updates and Treatment Advances
Systemic Therapies for the Treatment of Advanced Prostate Cancer
What is PSMA Theranostics? - a ProsTIC, Peter Mac animation
ProsTIC24 - Price Jackson: Medical Physicist: Dosimetry in Lu-PSMA Therapy
ProsTIC 2024 Publications Top 10 Deep Dive
PMNET Forum 2024: Radioligand Therapy
New Treatments for Advanced Prostate Cancer
EANM2020 - Dosimetry and Radiobiology of Lu PSMA treatment whole body tumour dose by Dr John Violet
Key considerations for the VISION trial of LuPSMA in mCRPC | Mary-Ellen Taplin
PSMA Targeting for Treatment of Advanced Prostate Cancer - 2021 Prostate Cancer Patient Conference
Bringing LuPSMA earlier | ProsTIC/PCF/ICIS Global Webinar
EANM2020 - Dosimetry and Radiobiology of Lu PSMA treatment whole body tumour dose by John Violet
Комментарии